ArticleWorld journal of gastroenterology2015
Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- External therapy of traditional Chinese medicine for treating irritable bowel syndrome with diarrhea: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Outcomes for a digital prescription mobile application for adults with irritable bowel syndrome: an uncontrolled trial.BMC gastroenterology · 2026Trial
- Efficacy and Safety of the Enterosorbent Silicolgel in Irritable Bowel Syndrome, IBS-D and IBS-M: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial.Neurogastroenterology and motility · 2025Trial
- Efficacy and dose response ofWorld journal of gastroenterology · 2023Trial
- Effect of Oral Intake ofNutrients · 2022Trial
- Agomelatine improves symptom severity and quality of life in diarrhea-predominant irritable bowel syndrome: insights from a randomized controlled clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- When Food Avoidance Meets Compatible Diagnostic Criteria: Avoidant/Restrictive Food Intake Disorder Features in Irritable Bowel Syndrome.Neurogastroenterology and motility · 2026Article
- Clinical characteristics and nutritional profiles of children with different irritable bowel syndrome subtypes: a retrospective hospital-based study.Translational pediatrics · 2026Article
- Clinical Features and Symptom Burden in Vietnamese Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Single-Center Cross-Sectional Study Using IBS-SSS and IBS-QoL Scores.Journal of clinical medicine · 2026Article
- Female Sexual Dysfunction and Irritable Bowel Syndrome: A Cross-Sectional Study in Jordanian Women.International journal of women's health · 2026Article
- Multi-omics analysis reveal clinical-gut-brain interactions in female ibs patients with adverse childhood experiences.Biology of sex differences · 2025Article
- Changji'an formula alleviates visceral hypersensitivity of a post-inflammatory IBS-D mouse model via NGF/TrkA signaling pathway.BMC complementary medicine and therapies · 2025Article
- Self-administered active versus sham acupressure for diarrhea predominant irritable bowel syndrome: a nurse-led randomized clinical trial.BMC nursing · 2025Article
- Initial Validation of the Eosinophilic Gastritis and Gastroenteritis Quality of Life Scale.Gastro hep advances · 2025Article
- Nurse-led self-management support to improve symptom management and self-reported outcomes in people with irritable bowel syndrome.Interdisciplinary nursing research · 2024Article
- Article
- ReFermFrontiers in medicine · 2024Article
- Neuroplasticity of the white matter tracts underlying recovery of diarrhea-predominant irritable bowel syndrome following acupuncture treatment.Frontiers in neuroscience · 2024Article
- An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with Constipation.Clinical and experimental gastroenterology · 2024Review
- Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box-Behnken Design, and Anti-Diarrheal Activity.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine effect of irritable bowel syndrome (IBS) subtype on IBS-specific quality of life (QOL) questionnaire and its subscales.
methodsWe studied IBS patients visiting our functional gastroenterology disorder clinic at a tertiary care center of Unites States. IBS and IBS subtype were diagnosed using Rome-III questionnaire. QOL was assessed using IBS-QOL questionnaire. IBS-QOL assesses quality of life along eight subscales: dysphoria, interference with activities, body image, health worry, food avoidance, social reactions, sexual health, and effect on relationships. IBS-QOL and its subscales were both scored on a range of 0-100 with higher scores suggestive of better QOL. Results of overall IBS-QOL scores and subscale scores are expressed as means with 95%CI. We compared mean IBS-QOL score and its subscales among various IBS-subtypes. Analysis of variance (ANOVA) was used to compare the mean difference between more than two groups after controlling for age and gender. A post-hoc analysis using Bonferroni correction was used only when P value for ANOVA was less than 0.05.
resultsOf 542 patients screened, 243 had IBS as per Rome-III criteria. IBS-mixed (IBS-M) was the most common IBS subtype (121 patients, 49.8%) followed by IBS- diarrhea (IBS-D) (56 patients, 23.1%), IBS-constipation (IBS-C) (54 patients, 22.2%) and IBS-unspecified (IBS-U) (12 patients, 4.9%). Overall IBS-QOL scores were significantly different among various IBS-subtypes (P = 0.01). IBS-QOL of patients with IBS-D (61.6, 95%CI: 54.0-69.1) and IBS-M (63.0, 95%CI: 58.1-68.0) was significantly lower than patients with IBS-C (74.5, 95%CI: 66.9-82.1) (P = 0.03 and 0.02 respectively). IBS-D patients scored significantly lower than IBS-C on food avoidance (45.0, 95%CI: 34.8-55.2 vs 61.1, 95%CI: 50.8-71.3, P = 0.04) and interference with activity (59.6, 95%CI: 51.4-67.7 vs 82.3, 95%CI: 74.1-90.6, P < 0.001). IBS-M patients had more interference in their activities (61.6, 95%CI: 56.3-66.9 vs 82.3, 95%CI: 74.1-90.6, P = 0.001) and greater impact on their relationships (73.3, 95%CI: 68.4-78.2 vs 84.7, 95%CI: 77.2-92.2, P = 0.02) than IBS-C patients. Patients with IBS-M also scored significantly lower than IBS-C on food avoidance (47.2, 95%CI: 40.7-53.7 vs 61.1, 95%CI: 50.8-71.3, P = 0.04) and social reaction (66.1, 95%CI: 61.1-71.1 vs 80.0, 95%CI: 72.1-87.7, P = 0.005).
conclusionIBS-D and IBS-M patients have lower IBS-QOL than IBS-C patients. Clinicians should recognize food avoidance, effects on daily activities and relationship problems in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.